Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 27, 2025
Teva Releases Q1 2025 Aide Memoire
GlobeNewswire
·
March 27, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website. Q1 2025 Aide Memoire Teva has prepared this …
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE
GlobeNewswire
·
March 27, 2025
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) …
Tilray Brands, Inc. to Announce Third Quarter Fiscal 2025 Financial Results on April 8, 2025
GlobeNewswire
·
March 27, 2025
NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis and wellness …
Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results
GlobeNewswire
·
March 27, 2025
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. …
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
GlobeNewswire
·
March 27, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. …
Abacus Global Management Reports Fourth Quarter and Full Year 2024 Results
GlobeNewswire
·
March 27, 2025
- Delivered Record Full Year Revenue and Growth While Executing on Strategic Acquisitions and Initiatives - - Fourth Quarter 2024 Total Revenue Grows 40% Year-over-Year to $33.2 Million - - Full-Year Policy Originations Grow 63% to 1,034 - - Initiating …
Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7
GlobeNewswire
·
March 27, 2025
DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor …
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
GlobeNewswire
·
March 27, 2025
Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failed A preliminary review of survival data showed 12-month LPFS of 64% (median 18.6 …
Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC localement avancé
GlobeNewswire
·
March 27, 2025
Les données montrent un profil de sécurité favorable et confirment la faisabilité de l’injection chez 12 patients atteints d’un cancer du poumon (CPNPC) localement avancé éligibles à une ré-irradiation et pour lesquels les lignes de traitement antérieures …
Precision Optics to Participate in the Lytham Partners 2025 Industrials & Basic Materials Investor Summit on April 1, 2025
GlobeNewswire
·
March 27, 2025
GARDNER, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, today announced that it will …
Tempest Reports Year End 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 27, 2025
• Granted Both Orphan Drug …
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
GlobeNewswire
·
March 27, 2025
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, …
Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025
GlobeNewswire
·
March 27, 2025
CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third …
Elutia Announces GPO Agreement with Advantus Health Partners to Expand Access to EluPro™
GlobeNewswire
·
March 27, 2025
Seventh GPO Agreement Signed Since EluPro’s Launch SILVER SPRING, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix products, announced that it has entered into an agreement …
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 27, 2025
– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025 – Initiation of expansion …
STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
·
March 27, 2025
HORSHAM, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
Accolade Stockholders Approve Merger Between Accolade and Transcarent
GlobeNewswire
·
March 27, 2025
SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the “Special Meeting”) held earlier today. The final, …
BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress
GlobeNewswire
·
March 27, 2025
CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) …
Iridex Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 27, 2025
MOUNTAIN VIEW, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal …
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
GlobeNewswire
·
March 27, 2025
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and …